GILD  Gilead Sciences Inc.




Health Care


Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.


Vuru Grade


Current Price

-1.2127 (-1.3626%)

Growth Price

Undervalued by 86.74%

Stability Price

Overvalued by 41.51%

Company Metrics

  • P/E 7.3709
  • P/S 3.7271
  • P/B 6.8278
  • EPS 11.91
  • Cash ROIC 49.59%
  • Cash Ratio 1.48
  • Dividend 1.72 / 1.95%
  • Avg. Vol. 12.11M
  • Shares 1.52B
  • Market Cap. 119.99B

Company Description

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life threatening diseases worldwide. Its products include Atripla, Truvada, Viread, Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, a amph... more

Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow


Gilead Sciences, Inc. (NASDAQ:GILD) defended at Argus following weak Q1
Daily Caller - 19 hours ago
Gilead Sciences, Inc. (NASDAQ:GILD) posted the Q1 earnings report on April 28. The earnings report failed to cater to investor expectations.
Gilead Sciences Q1 Key Insights - Seeking Alpha
Under Analyst's Radar: Gilead Sciences Inc. (GILD) - CWRU Observer
Gilead Sciences, Inc. Reports Disappointing Q1 Harvoni Sales
Motley Fool - Apr 29, 2016
Gilead Sciences (NASDAQ:GILD) started off 2016 on a bad note. Shares of the big biotech fell more than 17% by February before bouncing back.
Why Gilead Sciences, Inc. (GILD), Stericycle Inc (SRCL) and Western Digital ... -
Earnings Whispers: Gilead Sciences, Inc. (GILD), Amgen, Inc. (AMGN) - Daily Caller
Credit Suisse Weighs In Gilead Sciences, Inc. (GILD) and Celgene Corporation ...
Smarter Analyst - May 2, 2016
Credit Suisse analyst Alethia Young weighs in on biotech giants Gilead Sciences, Inc. (NASDAQ:GILD) and Celgene Corporation (NASDAQ:CELG) after both companies reported earnings.
3 Stocks to Watch on Friday: Amgen, Inc. (AMGN), Gilead Sciences, Inc. (GILD ... - Apr 29, 2016
3 Stocks to Watch on Friday: Amgen, Inc. (AMGN), Gilead The quarterly earnings reports keep coming, which will be driving the results in Amgen, Inc. (NASDAQ:AMGN) and Gilead Sciences, Inc. (NASDAQ:GILD) today. TiVo Inc. (NASDAQ:TIVO) will be on the ...
Jim Cramer Advises Viewers On Schlumberger, Gilead Sciences And Disney
Benzinga - 1 hour ago
Gilead Sciences, Inc. GILD has to make an acquisition and get another revenue stream, thinks Cramer. He didn't like its conference call.
Earnings Beat: Gilead Sciences, Inc. (GILD),, Inc. (AMZN), Groupon ...
Smarter Analyst - Apr 28, 2016
Biopharmaceutical company, Gilead Sciences, Inc. (NASDAQ:GILD), is scheduled to report first quarter earnings today, after the market closes.
Amazon, LinkedIn, Gilead, & More: Here's Why These Stocks Are Trending Today - Insider Monkey (blog)
After Hours: Amazon, LinkedIn, Baidu, Expedia Soar, Gilead Flops - Investor's Business Daily
3 Things to Watch in Gilead Sciences, Inc.'s First-Quarter Results
Motley Fool - Apr 23, 2016
After dropping more than 17% at one point, shares of Gilead Sciences (NASDAQ:GILD) are now back to roughly breakeven year to date.
Gilead Sciences, Inc. (NASDAQ:GILD) Stock Update - Daily Caller
Active Biotech Stock News: Gilead Sciences Inc. (GILD), Amgen Inc. (AMGN) - Zergwatch
Analyst Downgrades: Gilead Sciences, Inc., Skyworks Solutions Inc, and ...
Schaeffers Research (blog) - Apr 29, 2016
Analysts are weighing in on biotech stock Gilead Sciences, Inc. (NASDAQ:GILD), Apple Inc. (NASDAQ:AAPL) supplier Skyworks Solutions Inc (NASDAQ:SWKS), and healthcare interest Stericycle Inc (NASDAQ:SRCL).
Zacks' Insights: Apple Inc. (AAPL), Gilead Sciences, Inc. (GILD), Catalyst ...
Smarter Analyst - Apr 26, 2016
After the bell Tuesday, tech bellwether Apple Inc. (NASDAQ:AAPL) reported fiscal Q2 2016 earnings, and the company posted its first earnings miss in at least the past 5 quarters.
Analysts Rating Overview: Gilead Sciences, Inc. (NASDAQ:GILD) , UnitedHealth ...
Street Updates - May 3, 2016
Gilead Sciences, Inc. (NASDAQ:GILD) accumulated +0.90%, closing at $89.00 after floating between $86.75 and $89.45. The company has market capitalization of $121.65B.